Duo bids to halt breeding of human-animal hybrids

Charles Arthur Science Editor
Saturday 04 April 1998 23:02
Comments

A LEADING critic of the biotechnology industry has applied to patent half-human, half-animal experimental creatures made by fusing embryonic cells - in order to prevent them being bred.

Jeremy Rifkin says that he is seeking the patents on such a "chimera" in order to focus people's minds on the question of whether a human embryo can be considered intellectual property.

Mr Rifkin, who heads the business pressure group Foundation in Economic Trends, based in Washington DC, has applied jointly in the US for the patents with Stuart Newman, a New York scientist.

The creation of such a creature would be illegal in the UK under the 1990 Human Fertilisation and Embryology Act. But it would be legal in the US.

Neither applicant has actually produced such a chimera in the laboratory. Instead, they are exploiting a loophole in the US patent system which grants patents based on the description, rather than the demonstration, of a technique. The duo plan a similar application in Europe.

If the patents are granted, Mr Rifkin will hold them for "genetic conservancy" and refuse to license their use. He wants to spark a debate about the moral and ethical issues involved in patenting life and bioengineering humans. "There are serious constitutional issues involved here," he says. "Can a human embryo be considered intellectual property? This is the sort of question that we haven't debated in the US for 135 years - since slavery."

The problem, he says, is that the public does not really understand the consequences of the work currently going on in the biotechnology industry.

The creation of a human-animal chimera is the logical culmination of many projects being carried out by biotechnology companies. Already, it is common for transgenic bacteria and even animals to be given human genes. PPL, the company which helped produce Dolly the sheep, has a flock of sheep with a human gene to produce a protein for the treatment of cystic fibrosis.

PPL has applied for patents on cloning which its lawyers have confirmed would cover human cloning. And last year, Japanese scientists produced laboratory mice which had human chromosomes added.

A chimera would mingle the embryonic material of two species - which might have commercial applications. For example, a human-chimpanzee cross might be useful for testing new drugs to see if they would be harmful to humans or for examining human development.

But Thomas Murray, director of the Center for Biomedical Ethics at Case Western Reserve University, said: "If we put one human gene in an animal, or two or three, some people may get nervous but you're clearly not making a person yet. But when you talk about a hefty percentage of the cells being human ... this really is problematic. Then you have to ask these very hard questions about what it means to be human."

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in